EyePoint Pharmaceuticals Files 8-K
Ticker: EYPT · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1314102
| Field | Detail |
|---|---|
| Company | Eyepoint Pharmaceuticals, Inc. (EYPT) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financials, corporate-update
Related Tickers: EYPT
TL;DR
EYPT filed an 8-K on 10/14/25 updating financials and operations.
AI Summary
EyePoint Pharmaceuticals, Inc. filed an 8-K on October 14, 2025, reporting on results of operations, financial condition, and other events. The filing also includes financial statements and exhibits. The company was formerly known as pSivida Corp. and pSivida LTD.
Why It Matters
This 8-K filing provides an update on EyePoint Pharmaceuticals' operational and financial status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing providing standard corporate updates and financial information.
Key Players & Entities
- EyePoint Pharmaceuticals, Inc. (company) — Registrant
- pSivida Corp. (company) — Former company name
- pSivida LTD (company) — Former company name
- October 14, 2025 (date) — Date of earliest event reported
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it covers 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.
What are the 'Other Events' mentioned in the filing?
The filing lists 'Other Events' as an item information category, but the specific events are not detailed in the provided text.
When did EyePoint Pharmaceuticals change its name from pSivida Corp.?
The date of the name change from pSivida Corp. was June 19, 2008.
What is EyePoint Pharmaceuticals' principal executive office address?
The principal executive offices are located at 480 Pleasant Street, Suite C400, Watertown, Massachusetts 02472.
What is the SIC code for EyePoint Pharmaceuticals?
The Standard Industrial Classification (SIC) code for EyePoint Pharmaceuticals is 3826, which corresponds to LABORATORY ANALYTICAL INSTRUMENTS.
Filing Stats: 598 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-10-14 16:08:51
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Indi
Filing Documents
- d14832d8k.htm (8-K) — 25KB
- d14832dex991.htm (EX-99.1) — 27KB
- d14832dex992.htm (EX-99.2) — 36KB
- g14832ex99_2s10g1.jpg (GRAPHIC) — 92KB
- g14832ex99_2s11g1.jpg (GRAPHIC) — 103KB
- g14832ex99_2s12g1.jpg (GRAPHIC) — 40KB
- g14832ex99_2s13g1.jpg (GRAPHIC) — 93KB
- g14832ex99_2s14g1.jpg (GRAPHIC) — 94KB
- g14832ex99_2s15g1.jpg (GRAPHIC) — 118KB
- g14832ex99_2s16g1.jpg (GRAPHIC) — 108KB
- g14832ex99_2s17g1.jpg (GRAPHIC) — 122KB
- g14832ex99_2s18g1.jpg (GRAPHIC) — 100KB
- g14832ex99_2s19g1.jpg (GRAPHIC) — 106KB
- g14832ex99_2s1g1.jpg (GRAPHIC) — 44KB
- g14832ex99_2s20g1.jpg (GRAPHIC) — 97KB
- g14832ex99_2s21g1.jpg (GRAPHIC) — 131KB
- g14832ex99_2s22g1.jpg (GRAPHIC) — 32KB
- g14832ex99_2s23g1.jpg (GRAPHIC) — 107KB
- g14832ex99_2s24g1.jpg (GRAPHIC) — 88KB
- g14832ex99_2s25g1.jpg (GRAPHIC) — 84KB
- g14832ex99_2s26g1.jpg (GRAPHIC) — 105KB
- g14832ex99_2s27g1.jpg (GRAPHIC) — 44KB
- g14832ex99_2s2g1.jpg (GRAPHIC) — 204KB
- g14832ex99_2s3g1.jpg (GRAPHIC) — 109KB
- g14832ex99_2s4g1.jpg (GRAPHIC) — 100KB
- g14832ex99_2s5g1.jpg (GRAPHIC) — 68KB
- g14832ex99_2s6g1.jpg (GRAPHIC) — 128KB
- g14832ex99_2s7g1.jpg (GRAPHIC) — 109KB
- g14832ex99_2s8g1.jpg (GRAPHIC) — 42KB
- g14832ex99_2s9g1.jpg (GRAPHIC) — 108KB
- g14832g33h91.jpg (GRAPHIC) — 6KB
- 0001193125-25-239008.txt ( ) — 3781KB
- eypt-20251014.xsd (EX-101.SCH) — 3KB
- eypt-20251014_lab.xml (EX-101.LAB) — 17KB
- eypt-20251014_pre.xml (EX-101.PRE) — 11KB
- d14832d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT PHARMACEUTICALS, INC. Date: October 14, 2025 By: /s/ George O. Elston George O. Elston Executive Vice President and Chief Financial Officer